Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe study record now shows results have been posted and the design uses parallel assignment (replacing the prior single-group setup), along with updated results dates and related documents (Informed Consent Form and Study Protocol/SAP).SummaryDifference2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe site revision was updated to v3.5.3, replacing the previous v3.5.2. This reflects a metadata/version update rather than changes to study information.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.5.2 is now displayed on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedThe study page now displays 'Results Submitted' to indicate that trial results have been posted, replacing the previous 'No Results Posted' notification. The change clarifies the availability of outcomes for users reviewing the trial.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.